3/ 💡 KIMS leads with affordable healthcare, excelling in core markets while expanding into Tier 1 cities. Its EBITDA CAGR of 27% (FY24-27E) is backed by internal accruals and robust balance sheets. A solid BUY with a 21% upside! #KIMS #AffordableHealthcare https://t.co/ARjEXN1N11